Insight Molecular Diagnostics (IMDX) vs MDxHealth SA (MDXH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Insight Molecular Diagnostics (IMDX) has outperformed MDxHealth SA (MDXH) over the past year, losing 10.9% versus a loss of 87.2%. Insight Molecular Diagnostics is the larger company by market cap ($110.3 million vs $56.3 million), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMDX | MDXH |
|---|---|---|
| Share price | $3.37 | $0.5897 |
| Market cap | $110.28M | $56.27M |
| 1-day change | +2.74% | +1.58% |
| YTD return | -56.27% | -83.74% |
| 1-year return | -10.87% | -87.16% |
| 5-year return | -95.18% | — |
| EPS (TTM) | $-1.52 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.51 | $5.33 |
| 52-week low | $2.42 | $0.40 |
| Distance from 52-week high | -60.40% | -88.94% |
| Analyst consensus | none | none |
| Avg. price target upside | +144.81% | +205.24% |
| Average volume | 232.87K | 5.69M |
| Shares outstanding | 32.72M | 95.42M |
| Employees | 55 | 364 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMDX has outperformed MDXH by 76.3 percentage points over the past year.
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 55 employees
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Health Care · Medical Specialities · 364 employees
IMDX vs MDXH FAQ
Which is bigger, Insight Molecular Diagnostics or MDxHealth SA?
Insight Molecular Diagnostics (IMDX) is larger, with a market capitalization of $110.28M compared with $56.27M for MDxHealth SA (MDXH).
Which stock has performed better over the past year, IMDX or MDXH?
IMDX returned -10.87% over the past 12 months, compared with -87.16% for MDXH (price return, excluding dividends). Past performance does not predict future results.
Are Insight Molecular Diagnostics and MDxHealth SA in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for Insight Molecular Diagnostics and Medical Specialities for MDxHealth SA.